Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy. - Wikidata - wikimedia - TriplyDB

Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy.

Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy.

http://www.wikidata.org/entity/Q34519192

about

The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas.Inositol pyrophosphates mediate the DNA-PK/ATM-p53 cell death pathway by regulating CK2 phosphorylation of Tti1/Tel2 Genetic abnormalities in chronic lymphocytic leukemia: where we are and where we go Acquired chromosomal anomalies in chronic lymphocytic leukemia patients compared with more than 50,000 quasi-normal participants.Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia.Genome-wide assessment of recurrent genomic imbalances in canine leukemia identifies evolutionarily conserved regions for subtype differentiation.Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities.Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia.Detection of chromothripsis-like patterns with a custom array platform for chronic lymphocytic leukemia.Experimental designs for array comparative genomic hybridization technology Cross-platform assessment of genomic imbalance confirms the clinical relevance of genomic complexity and reveals loci with potential pathogenic roles in diffuse large B-cell lymphoma.Clinical application of targeted and genome-wide technologies: can we predict treatment responses in chronic lymphocytic leukemia?Diagnostic techniques and therapeutic challenges in patients with TP53 dysfunctional chronic lymphocytic leukemia.Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment.Chronic lymphocytic leukemia-associated chromosomal abnormalities and miRNA deregulation.Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemia.The inositol pyrophosphate pathway in health and diseases.Genomic arrays in chronic lymphocytic leukemia routine clinical practice: are we ready to substitute conventional cytogenetics and fluorescencein situhybridization techniques?

P2860

Q27024411-E3BC95DF-EB07-4717-BECF-938819276654 Q30299913-35395D13-BAD9-4E2F-9F4A-02CD94F19AE1 Q33570316-79580487-5F37-4534-BA1E-8B64EB2B6F0F Q33744997-93610566-FD7C-46EC-8A0D-87F1979B849F Q33818637-D81AB5F2-C76D-4487-A4B0-8AE3ED7F77AF Q34974058-5EF495B5-64F5-447E-B748-93DB6A7044C0 Q35650512-73FD69AC-FC1C-43B6-9E5F-3528EC8012F1 Q35926049-E701BDB7-5250-4E53-A492-3605A6C9246E Q36421804-8BCDE22E-9520-407D-98A7-98ED902C58C9 Q36799831-88F1E111-848B-4728-A5B5-5C93FAFCF24B Q37058063-3E003B72-6273-4FB3-A65A-8F354ECF9340 Q37132882-40896088-9763-4C38-B481-6B71E4E8D6D0 Q37618663-D1C0E71A-345C-4D42-88BD-C0C1A2A522C0 Q38008448-9BEE7DFE-A3B2-48B4-8900-0E1FF342C503 Q38970612-6A6D814F-249A-45A0-B433-73D721088EDE Q39670490-EFE0B16B-7D1C-48A6-AD9D-333D81B3B3BE Q44882002-847CC832-0CF1-4EBE-8F4C-04E059753E42 Q47250401-2AA556E7-BF4E-4329-A24B-F9DB17EABF9D Q58010100-97F51068-628C-4951-8596-7724B0E90297

P2860

Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy.

http://www.wikidata.org/entity/Q34519192

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Progressive but previously unt ...... esponse to chemoimmunotherapy.

@ast

Progressive but previously unt ...... esponse to chemoimmunotherapy.

@en

Progressive but previously unt ...... esponse to chemoimmunotherapy.

@nl

type

label

Progressive but previously unt ...... esponse to chemoimmunotherapy.

@ast

Progressive but previously unt ...... esponse to chemoimmunotherapy.

@en

Progressive but previously unt ...... esponse to chemoimmunotherapy.

@nl

prefLabel

Progressive but previously unt ...... esponse to chemoimmunotherapy.

@ast

Progressive but previously unt ...... esponse to chemoimmunotherapy.

@en

Progressive but previously unt ...... esponse to chemoimmunotherapy.

@nl

P1433

Q34519192-D9E39389-9795-441E-B010-2774F8CA6BE3

P1476

Q34519192-88241A1D-7C2C-4C24-89E1-06BC7FACFFF4

P2093

Q34519192-53B51E8B-83CA-4210-BB0B-2BBFA845D288

Q34519192-5C79D70F-01ED-444C-84B8-9B90128A94FF

Q34519192-73FF2618-FE3D-4F1F-9066-4295723B713E

Q34519192-7618ADBB-CB14-44B5-9DF7-36D3E0DFAC91

Q34519192-7B46F176-4895-4530-B59F-36C12EE74B98

Q34519192-842A8A8B-5CF3-4771-8D94-88C502B30E7C

Q34519192-9A580900-1378-46B0-9124-6B3121EF7926

Q34519192-C16AB88D-8CC3-4A75-B6C7-04C908BDA162

Q34519192-C4F9DA20-7DFC-41DF-B734-18DC4FA07B6E

Q34519192-C67A0BC4-8683-4AA3-8FE6-DCF12BD70822

P2860

Q34519192-3D9A700F-35BB-4B57-A849-292D5669AEA1

Q34519192-44737106-C25C-46B8-B745-C94A2F8FB9DC

Q34519192-582B9548-8FFE-483A-B22A-304B84653AB2

Q34519192-5D13FB8B-266C-4034-89CF-B72564BF9C6F

Q34519192-61624CCD-2A23-4B81-9C54-A2F4F3324A26

Q34519192-647C6430-B9BA-4CA1-B70F-A4B970A5BA60

Q34519192-649088C6-4FBC-4980-A192-0371BD1988D3

Q34519192-821A984A-123C-4BEB-8449-2B078C9FEB20

Q34519192-8C94AAEE-0E86-4338-9578-78D9A4CFA639

Q34519192-A8877E23-1F24-40B6-B6D3-EEF8E9D5395B

P304

Q34519192-72A4ED83-5625-4E32-A19E-380578F1C917

P31

Q34519192-964EEF98-560D-41C7-8668-7DCDF82318ED

P356

Q34519192-2B7ED5C6-614C-4726-A0D1-572EF5F6731B

P433

Q34519192-90E82808-0D8F-4794-9D51-F76C29E30CEE

P478

Q34519192-BA44E441-9D3C-48A1-8C76-AF09EEE4ADEF

P50

Q34519192-A40F66F7-AF5B-4F43-A832-C47EAE7DB59C

P577

Q34519192-EB6DE516-87EE-4614-A603-572007FDD4BE

P5875

Q34519192-33648533-A02C-4DB5-A247-9C871BBB9F9E

P698

Q34519192-BB0C8693-2B16-43AD-B6E6-A2523FBB8F27

P932

Q34519192-ECD3AF34-0882-4A1F-9AC5-FD41DFF502F3

P356

J.CANCERGENCYTO.2010.09.003

P1433

Cancer Genetics and Cytogenetics

P1476

Progressive but previously unt ...... esponse to chemoimmunotherapy.

@en

P2093

Daniel L Van Dyke

http://www.w3.org/2001/XMLSchema#string

Diane F Jelinek

http://www.w3.org/2001/XMLSchema#string

Esteban Braggio

http://www.w3.org/2001/XMLSchema#string

Jeanette E Eckel-Passow

http://www.w3.org/2001/XMLSchema#string

Neil E Kay

http://www.w3.org/2001/XMLSchema#string

Rafael Fonseca

http://www.w3.org/2001/XMLSchema#string

Renee C Tschumper

http://www.w3.org/2001/XMLSchema#string

Scott Vanwier

http://www.w3.org/2001/XMLSchema#string

Tait D Shanafelt

http://www.w3.org/2001/XMLSchema#string

Thomas Kipps

http://www.w3.org/2001/XMLSchema#string

P2860

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia

Integrated detection and population-genetic analysis of SNPs and copy number variation

Efficient calculation of interval scores for DNA copy number data analysis.

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL.

p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy.

Clinical utility of assessing ZAP-70 and CD38 in chronic lymphocytic leukemia.

Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia

Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.

P304

161-168

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CANCERGENCYTO.2010.09.003

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

203

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49681631

http://www.w3.org/2001/XMLSchema#string

P698

21156228

http://www.w3.org/2001/XMLSchema#string

P932

3026606

http://www.w3.org/2001/XMLSchema#string